We use cookies for a better user experience. Click here to know more about it. 


Global Live Cell Encapsulation Market Estimated to Grow With CAGR of 121.07% - QYResearch Report

Author: QYResearch  |   Published Date: 2021-07-12   |   Views: 51

Live cell encapsulation has long been proposed as a solution in modern medicine to many therapeutic problems. Cell encapsulation technology is used for the immobilization of cells within biocompatible and semipermeable membranes. The encapsulation of cells, instead of therapeutic products, is used to allow the delivery of molecules of interest for a longer time period as cells release these molecules of interest continuously. Furthermore, cells can be engineered for expressing the protein of interest in vivo without modifying the host’s genome. Cell encapsulation presents a significant advantage compared to protein encapsulation, as cell encapsulation allows a sustained and controlled delivery therapeutic molecules at a constant rate, thereby resulting in greater physiological concentrations.

Although a number of companies are now testing in human trials, no encapsulation device has been approved for commercial use to date. We predict that commercial products of some companies will enter the commercial production stage through clinical trials around 2022.

The global live cell encapsulation market is valued at US$ 10.78 million in 2022 and will reach US$ 257.46 million by the end of 2026, growing at a CAGR of 121.07% during 2021-2026.

The Live Cell Encapsulation market has been broadly segmented based on design, application. According to the research study. The Alginate, the major category of Live Cell Encapsulation, is valued at USD 6.05 million in 2022 and will be USD 120.93 million by 2026, reflecting a CAGR of 111.40% from 2022 to 2026.

Based on application, In global Live Cell Encapsulation market, Diabetes segment plays an important role, it is estimated to be USD 3.96 million by 2022 and is expected to be USD 81.83 million in 2026, expanding at a CAGR of 113.25% over 2021-2026.

Increase in adoption of novel drug delivery systems for the treatment of diseases, rise in technological advancements, surge in public-private investments to support the development of novel products, expanding research activities for establishing the clinical efficacy of cell encapsulation technologies, and increase in awareness among the people about the clinical role of encapsulated cells drive the global live cell encapsulation market. However, limited availability of raw materials of high quality, inflated manufacturing costs, and rise in adoption of alternative therapies are anticipated to hamper the growth of the global market.


Presently, companies Live Cell Encapsulation R & D status as follows:

Viacyte, Inc.

The PEC-Encap product candidate is also in clinical trials and is being developed as a functional cure for patients with type 1 diabetes.


Living Cell Technologies Ltd.

After securing regulatory approval based on animal trials, LCT moved from an encouraging initial clinical trial in four people with end-stage Parkinson’s disease to a larger Phase IIb trail in people with mid-stage Parkinson’s disease that lasted two years. The aim was to secure provisional consent from regulatory authorities to treat paying patients in New Zealand.

The 18-patient, Phase IIb trial of NTCELL encapsulated porcine choroid brain cells studied three groups of six patients. The active cohorts received 40 microcapsules, 80 microcapsules and 120 microcapsules implanted on each side of the brain. Two patients from each group had sham surgery.

The key measure of efficacy was motor function in the off state, that is, when recipients were not taking anti-Parkinsonian medications. Patients were scored using the Unified Parkinson’s Disease Rating Scale standard (UPDRS).

At the initial study endpoint of 26 weeks post-implant there was not a statistically significant difference between the groups who received NTCELL and the placebo group. At this point the study was unblinded (patients then knew if they were treated with placebo) and it was agreed to continue to monitor patients out to two years post-implant as per an extended trial protocol.

In May 2019, at 24 months post-implant there was a clinically relevant effect observed (<-6.45 points from baseline) in both the 80- and 40-capsule group. The effect of 80 capsules was greater than that of 40 capsules.

A Phase III clinical study with a larger number of patients will be required to provide compelling efficacy data required by regulatory agencies for marketing approval.

LCT is examining the feasibility of carrying out such a further clinical trial with NTCELL by consulting with an expert neurology advisory board.


Sigilon Therapeutics, Inc

Our pipeline currently spans three disease areas – including rare blood, lysosomal, and endocrine diseases – with product candidates designed to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient’s genes or immunosuppression.


Based on earlier preclinical data, we believe that SIG-001, our lead product candidate, has the potential to prevent bleeding episodes in patients with moderate-severe to severe hemophilia A by continuously secreting human FVIII. We are currently enrolling patients in a Phase 1/2 trial in this indication, as we continue to advance our other programs toward the clinic. Sigilon is leading execution of the program through IND and Eli Lilly and Company (Lilly), a global leader in diabetes, will develop and commercialize the program worldwide.


Sernova Corporation

Cell Pouch safety and biocompatibility has been demonstrated in multiple preclinical studies and ISO10993 biocompatibility studies. Cell Pouch has also been shown to be safe when tested in humans in a small clinical study.The Cell Pouch, when transplanted with insulin-producing islets, has demonstrated efficacy in three different small and large animal transplantation models (isograft, autograft and allograft) of diabetes, where animals achieved sustained glucose control.


Read More Information: https://www.qyresearch.com/index/detail/3149763/global-live-cell-encapsulation-market


About Us:

QYResearch provides Market Research Reports for clients all over the world. As of now, QYResearch data as following:

62000 + Clients(cover 100% the world strong 500 companies and most industries’ leading players such as TOP5 players)

7800 + Experts(most of them with more than 15 years’ experience in their industry and professional knowledge both in market and technology)

300 + Data Base(40% government related data base, 30% third part data base, 10% international agencies data base, 30% technology and market data base)

2 Million + Reports(cover almost all industries and most detailed products such as product model level research reports, where you can find all what you need in one shop)

1000 + Custom Research Projects(most clients need custom research service and QYResearch keeps offering good and depth service for them)

30 + Roles Data Interview Checking System(only QYResearch uses such interview system with more than 30 roles in order to confirm the data reliability)

13 + Years focus market research and continues to support the client success.


Media Contact:

Rahul Singh - Digital Marketing Director

Contact: +91 7028 920 828   +81-903-800-9273    +86-108-294-5717

Email: rahul@qyresearch.com

Sales Contact US:

USA Registered Office: QY Research, INC.

17890 Castleton, Suite 369,

City of industry, CA - 91748

Phone: +1-626-295-2442

Emails – enquiry@qyrsearch.com

Web – www.qyresearch.com

QYR Clients

  • csl
  • croozer
  • crital alert
  • cristal
  • corveneng
  • coperion
  • contijpi medical
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
More Clients...